A well-known pharmaceutical company has received FDA approval for Amivantamab-vmjw, a fully-human bispecific antibody that binds to the EGFR receptors and inhibits tumor growth. It is indicated for non-small cell lung cancer patients whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Lung cancer is one of the most common cancers worldwide and the major cause of cancer death. Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations are a group of mutations that cause rapid cell growth and, consequently, spread cancer.
Approximately 2 to 3 % of patients with non-small cell lung cancer have these mutations. FDA has approved the first targeted therapy for this subset of lung cancer patients. Amivantamab is a fully-human bispecific antibody that binds extracellularly on the EGFR receptors and inhibits tumor growth. Researchers have evaluated the…
